Opus Genetics IRD Proceeds from issuance of common stock and pre-funded warrants in connection with the March 2025 offering and March 2025 private placement
Proceeds from issuance of common stock and pre-funded warrants in connection with the March 2025 offering and March 2025 private placement at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept ird:ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInConnectionWithPrivateOfferingAndPrivatePlacement.
The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opus Genetics's proceeds from issuance of common stock and pre-funded warrants in connection with the march 2025 offering and march 2025 private placement.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Opus Genetics's proceeds from issuance of common stock and pre-funded warrants in connection with the march 2025 offering and march 2025 private placement?
- Opus Genetics (IRD) reported proceeds from issuance of common stock and pre-funded warrants in connection with the march 2025 offering and march 2025 private placement of $0 in Q1 2026.
- How has Opus Genetics's proceeds from issuance of common stock and pre-funded warrants in connection with the march 2025 offering and march 2025 private placement changed year-over-year?
- Opus Genetics's proceeds from issuance of common stock and pre-funded warrants in connection with the march 2025 offering and march 2025 private placement decreased by 100.0% year-over-year, from $5.98M to $0.
- What does proceeds from issuance of common stock and pre-funded warrants in connection with the march 2025 offering and march 2025 private placement mean?
- Represents the total cash proceeds received from the issuance of common equity and pre-funded warrants, often used by clinical-stage companies to bolster liquidity. This metric highlights the company's reliance on equity financing to fund ongoing research and development activities.